| Company/Division name | Alnylam Pharmaceuticals |
| Parent company | Alnylam Pharmaceuticals |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2027 |
| Capital investment ($): | 250 |
| City reshored to: | Norton |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Impact on domestic economy, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |
